{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T02:49:04Z","timestamp":1769568544600,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Institute of Information & Communications Technology Planning Evaluation (IITP), Korea government","award":["RS-2022-00155857"],"award-info":[{"award-number":["RS-2022-00155857"]}]},{"name":"Institute of Information & Communications Technology Planning Evaluation (IITP), Korea government","award":["RS-2022-00155857"],"award-info":[{"award-number":["RS-2022-00155857"]}]},{"name":"Institute of Information & Communications Technology Planning Evaluation (IITP), Korea government","award":["RS-2022-00155857"],"award-info":[{"award-number":["RS-2022-00155857"]}]},{"name":"Institute of Information & Communications Technology Planning Evaluation (IITP), Korea government","award":["RS-2022-00155857"],"award-info":[{"award-number":["RS-2022-00155857"]}]},{"name":"Institute of Information & Communications Technology Planning Evaluation (IITP), Korea government","award":["RS-2022-00155857"],"award-info":[{"award-number":["RS-2022-00155857"]}]},{"name":"National Research Foundation of Korea (NRF), Korea government","award":["RS-2023-00278597"],"award-info":[{"award-number":["RS-2023-00278597"]}]},{"name":"National Research Foundation of Korea (NRF), Korea government","award":["RS-2023-00278597"],"award-info":[{"award-number":["RS-2023-00278597"]}]},{"name":"National Research Foundation of Korea (NRF), Korea government","award":["RS-2023-00278597"],"award-info":[{"award-number":["RS-2023-00278597"]}]},{"name":"National Research Foundation of Korea (NRF), Korea government","award":["RS-2023-00278597"],"award-info":[{"award-number":["RS-2023-00278597"]}]},{"name":"National Research Foundation of Korea (NRF), Korea government","award":["RS-2023-00278597"],"award-info":[{"award-number":["RS-2023-00278597"]}]},{"name":"Korea Environmental Industry & Technology Institute (KEITI), Korea Ministry of Environment","award":["RS-2021-KE001333"],"award-info":[{"award-number":["RS-2021-KE001333"]}]},{"name":"Korea Environmental Industry & Technology Institute (KEITI), Korea Ministry of Environment","award":["RS-2021-KE001333"],"award-info":[{"award-number":["RS-2021-KE001333"]}]},{"name":"Korea Environmental Industry & Technology Institute (KEITI), Korea Ministry of Environment","award":["RS-2021-KE001333"],"award-info":[{"award-number":["RS-2021-KE001333"]}]},{"name":"Korea Environmental Industry & Technology Institute (KEITI), Korea Ministry of Environment","award":["RS-2021-KE001333"],"award-info":[{"award-number":["RS-2021-KE001333"]}]},{"name":"Korea Environmental Industry & Technology Institute (KEITI), Korea Ministry of Environment","award":["RS-2021-KE001333"],"award-info":[{"award-number":["RS-2021-KE001333"]}]},{"name":"Korea Machine Learning Ledger Orchestration for Drug Discovery Project (K-MELLODDY), Ministry of Health & Welfare and Ministry of Science and ICT","award":["RS-2024-00460694"],"award-info":[{"award-number":["RS-2024-00460694"]}]},{"name":"Korea Machine Learning Ledger Orchestration for Drug Discovery Project (K-MELLODDY), Ministry of Health & Welfare and Ministry of Science and ICT","award":["RS-2024-00460694"],"award-info":[{"award-number":["RS-2024-00460694"]}]},{"name":"Korea Machine Learning Ledger Orchestration for Drug Discovery Project (K-MELLODDY), Ministry of Health & Welfare and Ministry of Science and ICT","award":["RS-2024-00460694"],"award-info":[{"award-number":["RS-2024-00460694"]}]},{"name":"Korea Machine Learning Ledger Orchestration for Drug Discovery Project (K-MELLODDY), Ministry of Health & Welfare and Ministry of Science and ICT","award":["RS-2024-00460694"],"award-info":[{"award-number":["RS-2024-00460694"]}]},{"name":"Korea Machine Learning Ledger Orchestration for Drug Discovery Project (K-MELLODDY), Ministry of Health & Welfare and Ministry of Science and ICT","award":["RS-2024-00460694"],"award-info":[{"award-number":["RS-2024-00460694"]}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"crossref","award":["2710008763, KK-2401-01"],"award-info":[{"award-number":["2710008763, KK-2401-01"]}],"id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"crossref","award":["2710008763, KK-2401-01"],"award-info":[{"award-number":["2710008763, KK-2401-01"]}],"id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"crossref","award":["2710008763, KK-2401-01"],"award-info":[{"award-number":["2710008763, KK-2401-01"]}],"id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"crossref","award":["2710008763, KK-2401-01"],"award-info":[{"award-number":["2710008763, KK-2401-01"]}],"id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003705","name":"Korea Institute of Toxicology","doi-asserted-by":"crossref","award":["2710008763, KK-2401-01"],"award-info":[{"award-number":["2710008763, KK-2401-01"]}],"id":[{"id":"10.13039\/501100003705","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12403-2","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T02:46:21Z","timestamp":1766544381000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal accompanying diagnosis design through external validation of population pharmacokinetic models for moxifloxacin in tuberculosis patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Hyunjung","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woojin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Jung","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-woo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radojka M.","family":"Savic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwi-yeol","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"12403_CR1","doi-asserted-by":"crossref","unstructured":"Budak M, Cicchese JM, Maiello P, Borish HJ, White AG, Chishti HB et al. Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens. Jenner AL, editor. PLoS Comput Biol. 2023 June 15;19(6):e1010823.","DOI":"10.1371\/journal.pcbi.1010823"},{"issue":"1","key":"12403_CR2","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2666-5247(22)00359-7","volume":"4","author":"S Bagcchi","year":"2023","unstructured":"Bagcchi S. WHO\u2019s global tuberculosis report 2022. Lancet Microbe. 2023;4(1):e20.","journal-title":"Lancet Microbe"},{"key":"12403_CR3","doi-asserted-by":"crossref","unstructured":"Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009;48(12):1685\u201394.","DOI":"10.1086\/599040"},{"issue":"7","key":"12403_CR4","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/cid\/ciw566","volume":"63","author":"P Nahid","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive summary: official American thoracic society\/Centers for disease control and Prevention\/Infectious diseases society of America clinical practice guidelines: treatment of Drug-Susceptible tuberculosis. Clin Infect Dis. 2016;63(7):853\u201367.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"12403_CR5","doi-asserted-by":"publisher","first-page":"ofab660","DOI":"10.1093\/ofid\/ofab660","volume":"9","author":"HY Yun","year":"2022","unstructured":"Yun HY, Chang V, Radtke KK, Wang Q, Strydom N, Chang MJ, et al. Model-Based efficacy and toxicity comparisons of Moxifloxacin for Multidrug-Resistant tuberculosis. Open Forum Infect Dis. 2022;9(3):ofab660.","journal-title":"Open Forum Infect Dis"},{"issue":"suppl 1","key":"12403_CR6","first-page":"e20220803","volume":"76","author":"BPMD Silva","year":"2023","unstructured":"Silva BPMD, Almeida ASD, S\u00e9rgio MGDM, Gatto TC, Carasek VP, Yamamura M. Drug-Resistant tuberculosis and COVID-19: A scoping review on a new threat to antimicrobial resistance. Rev Bras Enferm. 2023;76(suppl 1):e20220803.","journal-title":"Rev Bras Enferm"},{"key":"12403_CR7","doi-asserted-by":"crossref","unstructured":"Van Den Elsen SH, Sturkenboom MG, Akkerman O, Barkane L, Bruchfeld J, Eather G, et al. Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study. BMJ Open. 2020 June;10(6):e035350.","DOI":"10.1136\/bmjopen-2019-035350"},{"issue":"4","key":"12403_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.12701\/yujm.2020.00626","volume":"37","author":"JG Jang","year":"2020","unstructured":"Jang JG, Chung JH. Diagnosis and treatment of multidrug-resistant tuberculosis. Yeungnam Univ J Med. 2020;37(4):277\u201385.","journal-title":"Yeungnam Univ J Med"},{"key":"12403_CR9","doi-asserted-by":"crossref","unstructured":"Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, Dakum P et al. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant\/multi-drug resistant tuberculosis in Nigeria. Furin J, editor. PLoS ONE. 2020;15(12):e0241065.","DOI":"10.1371\/journal.pone.0241065"},{"issue":"8","key":"12403_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.15585\/mmwr.mm7108a1","volume":"71","author":"W Carr","year":"2022","unstructured":"Carr W, Kurbatova E, Starks A, Goswami N, Allen L, Winston C. Interim guidance: 4-Month Rifapentine-Moxifloxacin regimen for the treatment of Drug-Susceptible pulmonary Tuberculosis \u2014 United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(8):285\u20139.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"12403_CR11","doi-asserted-by":"crossref","unstructured":"Chirehwa MT, Resendiz-Galvan JE, Court R, De Kock M, Wiesner L, De Vries N et al. Optimizing Moxifloxacin dose in MDR-TB participants with or without Efavirenz coadministration using population Pharmacokinetic modeling. Antimicrob Agents Chemother. 2023;e01426\u201322.","DOI":"10.1128\/aac.01426-22"},{"issue":"2","key":"12403_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1128\/AAC.00414-06","volume":"51","author":"RK Shandil","year":"2007","unstructured":"Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, et al. Moxifloxacin, ofloxacin, sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007;51(2):576\u201382.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"12403_CR13","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","volume":"208","author":"JG Pasipanodya","year":"2013","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464\u201373.","journal-title":"J Infect Dis"},{"issue":"2","key":"12403_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/jac\/dkx421","volume":"73","author":"MT Heinrichs","year":"2018","unstructured":"Heinrichs MT, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, Bablishvili N, et al. Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical Pharmacokinetic study. J Antimicrob Chemother. 2018;73(2):477\u201383.","journal-title":"J Antimicrob Chemother"},{"key":"12403_CR15","doi-asserted-by":"crossref","unstructured":"Sarathy J, Blanc L, Alvarez-Cabrera N, O\u2019Brien P, Dias-Freedman I, Mina M et al. Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations. Antimicrob Agents Chemother. 2019;63(5).","DOI":"10.1128\/AAC.02516-18"},{"key":"12403_CR16","doi-asserted-by":"crossref","unstructured":"Ghimire S, Bolhuis MS, Sturkenboom MGG, Akkerman OW, De Lange WCM, Van Der Werf TS, et al. Incorporating therapeutic drug monitoring into the world health organization hierarchy of tuberculosis diagnostics. Eur Respir J. 2016 June;47(6):1867\u20139.","DOI":"10.1183\/13993003.00040-2016"},{"key":"12403_CR17","doi-asserted-by":"crossref","unstructured":"van den Elsen SHJ, Sturkenboom MGG, Akkerman OW, Manika K, Kioumis IP, van der Werf TS et al. Limited sampling strategies using linear regression and the bayesian approach for therapeutic drug monitoring of Moxifloxacin in tuberculosis patients. Antimicrob Agents Chemother. 2019 July;63(7).","DOI":"10.1128\/AAC.00384-19"},{"issue":"1","key":"12403_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1128\/AAC.01478-13","volume":"58","author":"SP Zvada","year":"2014","unstructured":"Zvada SP, Denti P, Sirgel FA, Chigutsa E, Hatherill M, Charalambous S, et al. Moxifloxacin population pharmacokinetics and model-based comparison of efficacy between Moxifloxacin and Ofloxacin in African patients. Antimicrob Agents Chemother. 2014;58(1):503\u201310.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"12403_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503\u201312.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"12403_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/pharmaceutics15020569","volume":"15","author":"S Wang","year":"2023","unstructured":"Wang S, Yin Q, Yang M, Cheng Z, Xie F. External evaluation of population Pharmacokinetic models of methotrexate for Model-Informed precision dosing in pediatric patients with acute lymphoid leukemia. Pharmaceutics. 2023;15(2):569.","journal-title":"Pharmaceutics"},{"issue":"10","key":"12403_CR21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/aps.2014.76","volume":"35","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhang H, nian, Niu C, he, Gao P, Chen Y jun, Peng J, et al. Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy. Acta Pharmacol Sin. 2014;35(10):1342\u201350.","journal-title":"Acta Pharmacol Sin"},{"key":"12403_CR22","doi-asserted-by":"crossref","unstructured":"Strydom N, Gupta SV, Fox WS, Via LE, Bang H, Lee M et al. Tuberculosis drugs\u2019 distribution and emergence of resistance in patient\u2019s lung lesions: A mechanistic model and tool for regimen and dose optimization. Murray M, editor. PLoS Med. 2019;16(4):e1002773.","DOI":"10.1371\/journal.pmed.1002773"},{"key":"12403_CR23","doi-asserted-by":"crossref","unstructured":"Chang MJ, Jin B, Chae Jwoo, Yun H, yeol, Kim ES, Lee YJ, et al. Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis. Int J Antimicrob Agents. 2017 June;49(6):677\u201387.","DOI":"10.1016\/j.ijantimicag.2017.01.024"},{"key":"12403_CR24","doi-asserted-by":"crossref","unstructured":"Pranger AD, Kosterink JG, van Altena R, Aarnoutse RE, van der Werf TS, Uges DR, et al. Limited-sampling strategies for therapeutic drug monitoring of Moxifloxacin in patients with tuberculosis. Ther Drug Monit. 2011 June;33(3):350\u20134.","DOI":"10.1097\/FTD.0b013e31821b793c"},{"issue":"4","key":"12403_CR25","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1128\/AAC.04659-14","volume":"59","author":"K \u00d6brink-Hansen","year":"2015","unstructured":"\u00d6brink-Hansen K, Hardlei TF, Brock B, Jensen-Fangel S, Kragh Thomsen M, Petersen E, et al. Moxifloxacin Pharmacokinetic profile and efficacy evaluation in empiric treatment of Community-Acquired pneumonia. Antimicrob Agents Chemother. 2015;59(4):2398\u2013404.","journal-title":"Antimicrob Agents Chemother"},{"key":"12403_CR26","doi-asserted-by":"crossref","unstructured":"Al-Shaer MH, Alghamdi WA, Alsultan A, An G, Ahmed S, Alkabab Y, et al. Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic\/pharmacodynamic target attainment to guide dose selection. Antimicrob Agents Chemother. 2019 July;63(7):e00279\u201319.","DOI":"10.1128\/AAC.00279-19"},{"issue":"8","key":"12403_CR27","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1177\/0091270010381498","volume":"51","author":"JA Florian","year":"2011","unstructured":"Florian JA, Torn\u00f8e CW, Brundage R, Parekh A, Garnett CE. Population Pharmacokinetic and Concentration-QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol. 2011;51(8):1152\u201362.","journal-title":"J Clin Pharmacol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12403-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12403-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:30:59Z","timestamp":1769517059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12403-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12403"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12403-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were approved by relevant national controlling bodies and ethical committees at the different sites and was done in accordance with Good Clinical Practice Guidelines and the principles of the Declaration of Helsinki (Study 1 [B-130191-001] by Institutional Review Board [IRB] at Seoul National University Bundang Hospital in Republic of Korea; Study 2 [ClinicalTrials.gov Identifier NCT0081646, registered on (2008-12-29)] by IRB at Pusan National University Hospital, Asan Medical Center and National Medical Center in Republic of Korea; Study 3 [ClinicalTrials.gov Identifier NCT01498419] by IRB at Karl Bremer Hospital, University of Cape Town Lung Institute Ltd, KwaZulu-Natal Research Institute for Tuberculosis and HIV, CHRU Themba Lethu Clinic, Klerksdorp Tshepong Hospital, Tembisa Hospital in South Africa and Ifakara Health Institute, Mbeya Medical Research Programme in Tanzania; Study 4 [ClinicalTrials.gov Identifier NCT02193776] by IRB at Tembisa Hospital, Klerksdorp Tshepong Hospital, TASK Applied Science, University of Cape Town Lung Institute Ltd, Tuberculosis & HIV Investigative Network of KwaZulu-Natal, CHRU Themba Lethu Clinic, Helen Joseph Hospital in South Africa and Ifakara Health Institute, Mbeya Medical Research Programme in Tanzania and Uganda Case Western Reserve University Research Collaboration in Uganda; Study 5 [ClinicalTrials.gov Identifier NCT02342886] by IRB at National Center for Tuberculosis and Lung Diseases in Georgia, Keny Medical Research Institute in Kenya, Pusat Perubatan Universiti Kebangsaan, Universiti Teknologi MARA, Institute of Respiratory Medicine in Malaysia, Philippine General Hospital, Vincent Balang, Lung Center of Philippines in Philippines; TASK, University of Cape Town Lung Institute, Setshaba Research Centre, Tembisa Hospital, CHRU Themba Lethu Clinic, Durban International Clinical Trials Unit, Klerksdorp Tshepong Hospital, Synexus SA, Madibeng Centre for Research, Tuberculosis & HIV Investigative Network of Kwazulu Natal, Aurum Institute, Aurum Institute: Rustenberg in South Africa, Ifakara Health Institute, Mbeya Medical Research Programme, Kilimanjaro National Institute for Medical Research in Tanzania, Uganda CWRU Research Collaboration in Uganda and Centre for Infectious Disease Research in Zambia). All patients provided written informed consent before the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"183"}}